Detalhe da pesquisa
1.
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 402(10403): 705-719, 2023 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385278
2.
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
Diabetes Obes Metab
; 25(2): 468-478, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200477
3.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Lancet
; 397(10286): 1736-1748, 2021 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33894838
4.
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Diabetes Obes Metab
; 24(1): 94-105, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514682
5.
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
JAMA
; 327(2): 138-150, 2022 01 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015037
6.
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
JAMA
; 325(14): 1403-1413, 2021 04 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33625476
7.
Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes.
Int J Obes (Lond)
; 44(5): 990-998, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31949295
8.
Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials.
EClinicalMedicine
; 55: 101737, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36467859
9.
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
Postgrad Med
; 134(sup1): 28-36, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36691307
10.
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.
Postgrad Med
; 134(1): 14-19, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34775881
11.
Weight History in Clinical Practice: The State of the Science and Future Directions.
Obesity (Silver Spring)
; 28(1): 9-17, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31858735
12.
Impact on psychosocial outcomes of a nationally available weight management program tailored for individuals with type 2 diabetes: Results of a randomized controlled trial.
J Diabetes Complications
; 31(5): 891-897, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28319001
13.
Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes.
Obesity (Silver Spring)
; 24(11): 2269-2277, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27804264